[The no-reflow phenomenon following percutaneous coronary intervention]
Related Experiment Video
Updated: Jun 18, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Shmuel Schwartzenberg1, Amir Halkin, Ariel Finkelstein
1Department of Cardiology, Sourasky Tel Aviv Medical Center, Tel Aviv, Israel. sschwartzenberg@gmail.com
Insights
The no-reflow phenomenon, a myocardial perfusion defect, negatively impacts outcomes in acute myocardial infarction patients with risk factors. Understanding its causes, like microemboli, aids new diagnostic and treatment strategies.
Area of Science:
- Cardiovascular Medicine
- Pathophysiology
- Microvascular Biology
Context:
- The no-reflow phenomenon occurs despite successful coronary artery reperfusion.
- It is characterized by impaired blood flow in the heart's microvascular network.
- This condition is frequently observed in acute myocardial infarction (AMI) patients with cardiovascular risk factors.
Purpose:
- To elucidate the pathophysiological mechanisms underlying the no-reflow phenomenon.
- To highlight its significance as an independent negative prognostic indicator in AMI.
- To review recent advancements in diagnostic and therapeutic approaches.
Summary:
- No-reflow is a myocardial perfusion defect resulting from microvascular dysfunction post-reperfusion.
- It is attributed to microemboli and intracellular changes during reperfusion.
- Its prevalence increases with cardiovascular risk factors, signaling a poor prognosis.
Impact:
- Improved understanding of no-reflow pathophysiology.
- Potential for enhanced diagnostic accuracy in identifying at-risk patients.
- Foundation for developing targeted treatments to improve microvascular function and patient outcomes.
Abstract:
The no-reflow phenomenon after successful coronary artery perfusion is caused by a myocardial perfusion defect due to impaired blood flow in the microvascular bed. This phenomenon is more prevalent among acute myocardial infarction patients who have additional cardiovascular risk factors, and its presence constitutes an independent negative prognostic sign. The impaired microvascular myocardial blood flow is caused by microemboli and by intracellular processes taking place during the reperfusion phase. In the last few years, many studies have been published regarding new diagnostic and treatment modalities based on a better understanding of the pathophysiological processes implicated.
